Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16454319 | 0.85 | MAPT (0.46) | MAPTPOLBPDPK1CNR2ALDH1A1 | |
| SCHEMBL17816208 | 0.80 | POLB (0.41) | MAPTPOLBCNR2NPSR1L3MBTL1 | |
| SCHEMBL17808268 | 0.79 | LMNA (0.58) | MAPTPOLBCNR2L3MBTL1 | |
| SCHEMBL31438196 | 0.75 | ALDH1A1 (0.56) | MAPTPOLBALDH1A1CA12CA1 | |
| SCHEMBL17816233 | 0.74 | CYP1A2 (0.41) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL17816217 | 0.72 | KMT2A (0.43) | POLBALDH1A1NPSR1 | |
| SCHEMBL18529726 | 0.72 | FNTA (0.44) | MAPTESRRGCNR2ALDH1A1CA12 | |
| SCHEMBL17816212 | 0.72 | NPSR1 (0.44) | MAPTPOLBALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL30241011 | 0.72 | LMNA (0.60) | ALOX15 | |
| SCHEMBL19251863 | 0.71 | CA1 (0.56) | MAPTALDH1A1L3MBTL1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| EP-3030081-B1 | PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159781-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | MAPT 4454/4885POLB 1307/4885PDPK1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.